Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_assertion type Assertion NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_head.
- NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_provenance.
- NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_assertion evidence source_evidence_literature NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_provenance.
- NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_assertion SIO_000772 22210719 NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_provenance.
- NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_assertion wasDerivedFrom befree-20150227 NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_provenance.
- NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_assertion wasGeneratedBy ECO_0000203 NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_provenance.